RET and colorectal carcinoma: Importantly, we include multiple PDX models across both NSCLC and CRC, and we also include important controls that were omitted from other published studies by comparing efficacy in RET fusion-positive tumors to RET fusion-negative tumors, and RET kinase inhibition to standard of care chemotherapy.